Regulatory approval
Published by the Health Canada. Approved
ERBITUX (cetuximab) is indicated as a single agent for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in patients who have failed both irinotecan- and oxaliplatin-based regimens and who have received a fluoropyrimidine.
This is written in the approval document.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HC (1) | EGFR positive, Wild type KRAS | Colorectal Adenocarcinoma | Cetuximab |